Opus Genetics Financials
| IRD Stock | 2.08 0.05 2.35% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | 2.92 |
|
|
The financial analysis of Opus Genetics is a critical element in measuring its lifeblood. Investors should not minimize Opus Genetics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Opus | Select Account or Indicator | Build AI portfolio with Opus Stock |
Understanding current and past Opus Genetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Opus Genetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Opus Genetics' assets may result in an increase in income on the income statement.
Please note, the presentation of Opus Genetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Opus Genetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Opus Genetics' management manipulating its earnings.
Opus Genetics Stock Summary
Opus Genetics competes with Acumen Pharmaceuticals, Seer, Agenus, Inovio Pharmaceuticals, and VistaGen Therapeutics. Opus Genetics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US67577R1023 |
| Business Address | 8 Davis Drive, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | opusgtx.com |
| Phone | 984 884 6030 |
Opus Genetics Key Financial Ratios
| Return On Equity | -3.39 | ||||
| Operating Margin | (2.70) % | ||||
| Price To Sales | 9.99 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) |
Opus Genetics Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 26.1M | 49.0M | 53.9M | 36.9M | 42.4M | 34.0M | |
| Other Current Liab | 1.7M | 1.4M | 1.9M | 8.1M | 9.4M | 9.8M | |
| Net Debt | (24.0M) | (42.6M) | (50.5M) | (30.3M) | (27.3M) | (28.7M) | |
| Retained Earnings | (89.4M) | (71.5M) | (81.5M) | (139.0M) | (125.1M) | (118.8M) | |
| Accounts Payable | 1.6M | 1.1M | 2.2M | 3.1M | 3.6M | 3.8M | |
| Cash | 24.5M | 42.6M | 50.5M | 30.3M | 34.9M | 30.4M | |
| Other Current Assets | 1.3M | 1.5M | 1.1M | 515K | 592.3K | 1.1M | |
| Total Liab | 3.9M | 2.8M | 4.0M | 30.1M | 34.7M | 36.4M | |
| Total Current Assets | 26.1M | 49.0M | 53.9M | 36.6M | 42.1M | 33.9M | |
| Net Invested Capital | 22.8M | 46.2M | 49.9M | 6.7M | 7.7M | 7.3M | |
| Net Working Capital | 22.2M | 46.2M | 49.9M | 25.3M | 29.1M | 34.8M |
Opus Genetics Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Operating Income | (22.7M) | 18.2M | (10.6M) | (62.1M) | (55.9M) | (53.1M) | |
| Ebit | (56.7M) | 18.2M | (10.0M) | (57.5M) | (51.8M) | (49.2M) | |
| Research Development | 15.2M | 14.4M | 17.7M | 26.9M | 30.9M | 32.4M | |
| Ebitda | (56.7M) | 18.2M | (10.0M) | (57.5M) | (51.8M) | (49.2M) | |
| Income Before Tax | (56.7M) | 18.2M | (10.0M) | (57.5M) | (51.8M) | (49.2M) | |
| Net Income | (56.7M) | 17.9M | (10.0M) | (57.5M) | (51.8M) | (49.2M) | |
| Total Revenue | 589K | 39.9M | 19.0M | 11.0M | 12.6M | 15.5M | |
| Gross Profit | 589K | 39.9M | 19.0M | 11.0M | 12.6M | 15.5M |
Opus Genetics Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 8.1M | 18.1M | 7.9M | (20.2M) | (18.2M) | (17.3M) | |
| Free Cash Flow | (19.4M) | 14.3M | (1.1M) | (25.6M) | (23.0M) | (21.9M) | |
| Other Non Cash Items | 35.2M | 170K | 1.3M | 25.5M | 29.3M | 30.8M | |
| Net Income | (56.7M) | 17.9M | (10.0M) | (57.5M) | (51.8M) | (49.2M) | |
| End Period Cash Flow | 24.5M | 42.6M | 50.5M | 30.3M | 34.9M | 30.4M |
Opus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Opus Genetics's current stock value. Our valuation model uses many indicators to compare Opus Genetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Opus Genetics competition to find correlations between indicators driving Opus Genetics's intrinsic value. More Info.Opus Genetics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Opus Genetics' Return On Equity is projected to drop based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Opus Genetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Opus Genetics Systematic Risk
Opus Genetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Opus Genetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Opus Genetics correlated with the market. If Beta is less than 0 Opus Genetics generally moves in the opposite direction as compared to the market. If Opus Genetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Opus Genetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Opus Genetics is generally in the same direction as the market. If Beta > 1 Opus Genetics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Opus Genetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Opus Genetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Opus Genetics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Opus Genetics January 6, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Opus Genetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Opus Genetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Opus Genetics based on widely used predictive technical indicators. In general, we focus on analyzing Opus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Opus Genetics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.93 | |||
| Information Ratio | 0.0613 | |||
| Maximum Drawdown | 26.5 | |||
| Value At Risk | (6.96) | |||
| Potential Upside | 6.7 |
Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |